Replicating viral vectors for cancer therapy: strategies to synergize with host immune responses

摘要: Tumour-specific replicating (oncolytic) viruses are novel anticancer agents, currently under intense investigation in preclinical studies and phase I-III clinical trials. Until recently, most have focused on the direct antitumour properties of these viruses. There is now an increasing body evidence indicating that host immune responses may be critical to efficacy oncolytic virotherapy. Although response can rapidly restrict viral replication, thereby limiting therapy, virotherapy also has potential induce potent antitumoural effectors destroy those cancer cells, which not directly lysed by virus. In this review, we discuss role system terms antiviral responses, as well strategies evade or promote favour improved therapeutic potentials.